1. Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial. (14th November 2019) Authors: Stintzing, S; Wirapati, P; Lenz, H -J; Neureiter, D; Fischer von Weikersthal, L; Decker, T; Kiani, A; Kaiser, F; Al-Batran, S; Heintges, T; Lerchenmüller, C; Kahl, C; Seipelt, G; Kullmann, F; Moehler, M; Scheithauer, W; Held, S; Modest, D P; Jung, A; Kirchner, T Journal: Annals of oncology Issue: Volume 30:Number 11(2019) Page Start: 1796 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗